NewsCLINICALTRIALS.GOVWednesday, January 28, 2026 · January 28, 2026
New recruiting trial: CAMK2-related Synapthopathies Natural History Study
WHY IT MATTERS
New clinical trials expand access to investigational treatments for rare disease patients.
The key endpoint for this prospective cohort study is: Mapping of the disease course of all known patients (both children and adults, international) with a CAMK2 mutation, for which ENCORE has founded an expert clinic, and therefore has a substantial and active neuroscientific research arm combined
Related news
ClinicalTrials.gov · April 14, 2026
New recruiting trial: Evaluation of Socio-professional Inclusion for Young Adults Aged 15-25 Living With a Rare Genetic Disability
Rare diseases are often synonymous with difficulties for sufferers, whether physical, mental or social. Patients sufferi…
ClinicalTrials.gov · April 13, 2026
New recruiting trial: Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
This study will collect, annotate, and sequence biospecimens (blood, tissue, urine, saliva and surgery drainage) from pa…
ClinicalTrials.gov · March 3, 2026
New recruiting trial: Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)
This observational, multicenter, retrospective and prospective study aims to evaluate the impact of intensified lipid-lo…
ClinicalTrials.gov · February 20, 2026
New recruiting trial: FACE.S-4-KIDS : A Deep Phenotyping Database of Craniofacial Anomalies During Development With 4 Pilot Projects
FACE.S-4-KIDS is an ambitious database project addressing the scientific question of the variable expression of craniofa…